TherapeuticsMD (Nasdaq:TXMD) - Prezzo delle azioni, notizie e analisi

TXMD Panoramica delle azioni

TherapeuticsMD, Inc. opera negli Stati Uniti come società farmaceutica a responsabilità limitata. Maggiori dettagli

TXMD analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $15M )

Non ha entrate significative ( $2M )

TherapeuticsMD, Inc. Concorrenti

Cumberland Pharmaceuticals

NasdaqGS:CPIX

US$15.2m

LiveCare

OTCPK:LVCE

US$17.1m

Marinus Pharmaceuticals

NasdaqGM:MRNS

US$17.8m

Aytu BioPharma

NasdaqCM:AYTU

US$9.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per TherapeuticsMD
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.37
Massimo di 52 settimane	US$2.99
Minimo di 52 settimane	US$1.15
Beta	1.14
1Variazione di 1 mese	-13.02%
Variazione a 3 mesi	-22.60%
Variazione di 1 anno	-53.87%
3Variazione a 3 anni	-95.26%
Variazione a 5 anni	-98.91%
Variazione dall'IPO	-97.26%

Notizie e aggiornamenti recenti

Recent updates

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

Jul 06

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Jun 16

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Mar 14

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Oct 22

TherapeuticsMD: The Long Road To Profitability

Jul 08

TherapeuticsMD drops 3% despite consensus beating Q1 results

May 06

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

Feb 24

TherapeuticsMD: Annovera May Save The Day

Feb 04

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

Jan 29

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

Jan 27

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

Dec 30

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

Dec 09

TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook

Nov 25

Therapeutics MD EPS beats by $0.01, beats on revenue

Nov 09

Rendimenti per gli azionisti

	TXMD	US Pharmaceuticals	US Mercato
7D	-2.1%	-1.4%	0.3%
1Y	-53.9%	10.8%	31.1%

Ritorno vs Industria: TXMD ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 10.8 % nell'ultimo anno.

Rendimento vs Mercato: TXMD ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.1 % nell'ultimo anno.

Volatilità dei prezzi

Is TXMD's price volatile compared to industry and market?
TXMD volatility
TXMD Average Weekly Movement	5.3%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: TXMD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di TXMD è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2008	1	Marlan Walker	www.therapeuticsmd.com

TherapeuticsMD, Inc. opera negli Stati Uniti come società farmaceutica a responsabilità limitata. Ha un accordo di licenza con Mayne Pharma per la commercializzazione dei prodotti vitaminici prenatali su prescrizione IMVEXXY, BIJUVA e ANNOVERA, venduti con i marchi BocaGreenMD e vitaMedMD. L'azienda vende i suoi prodotti farmaceutici soggetti a prescrizione e le vitamine prenatali attraverso distributori all'ingrosso e distributori di farmacie al dettaglio.

TherapeuticsMD, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di TherapeuticsMD con la sua capitalizzazione di mercato?
TXMD statistiche fondamentali
Capitalizzazione di mercato	US$15.34m
Guadagni(TTM)	-US$3.97m
Ricavi(TTM)	US$1.60m

9.9x

Rapporto P/S

-4.0x

Rapporto P/E

TXMD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TXMD Conto economico (TTM)
Ricavi	US$1.60m
Costo del fatturato	US$0
Profitto lordo	US$1.60m
Altre spese	US$5.56m
Guadagni	-US$3.97m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.34
Margine lordo	100.00%
Margine di profitto netto	-248.56%
Rapporto debito/patrimonio netto	0%

Come si è comportato TXMD nel lungo periodo?

Vedi performance storica e confronto

TXMD Panoramica delle azioni

Analisi del rischio

TherapeuticsMD, Inc. Concorrenti

NasdaqGS:CPIX

US$15.2m

OTCPK:LVCE

US$17.1m

NasdaqGM:MRNS

US$17.8m

NasdaqCM:AYTU

US$9.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD raises $7M in private placement

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD appoints interim co-CEOs

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

Therapeutics MD Q2 Earnings Preview

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

TherapeuticsMD receives $15M equity investment from Rubric Capital

TherapeuticsMD jumps 12% as top investor discloses insider purchase

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD plunges 42% as merger agreement ends

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Consensus forecasts updated

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Consensus forecasts updated

Price target decreased to US$3.75

Co-Founder notifies of intention to sell stock

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Co-Founder notifies of intention to sell stock

Consensus revenue estimates fall by 24%

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought US$579k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought US$725k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

No longer forecast to breakeven

TherapeuticsMD: The Long Road To Profitability

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

Co-Founder exercised options and sold US$70k worth of stock

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

TherapeuticsMD drops 3% despite consensus beating Q1 results

Revenue and earnings beat expectations

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

TherapeuticsMD: Annovera May Save The Day